Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered ...
A new Cedars-Sinai Cancer study shows that patients with advanced liver cancer who receive immunotherapy to shrink their ...
Pivotal Phase III liver cancer study enrolling in Europe and Israel RAMAT GAN, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ...
MedPage Today on MSN
After Hepatitis C Cure, MASLD May Boost Liver Cancer Risk
WASHINGTON -- Liver cancer risk after hepatitis C virus (HCV) cure was significantly greater in patients with metabolic ...
News Medical on MSN
Steatotic Liver Disease, Cancer: Pathogenesis to Therapy
Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), ...
As Liver Cancer Awareness Month ends, Drs. Vogel and Yarchoan highlight the urgent need for greater awareness, support and ...
“The biggest risk for lung cancer is cigarette smoking,” says Waqar. It’s estimated that 85% of lung cancer deaths are ...
Colon cancer, also known as colorectal cancer, is one of the most frequent and aggressive cancers. According to the WHO, it ...
The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.
Dr Moni Abraham Kuriakose –co-founder, medical director, and CEO of Karkinos Kerala – is a leading surgical oncologist and ...
Conclusions TACE plus targeted immunotherapy yields high response and surgical conversion rates with acceptable toxicity in uHCC. Patients with CNLC stage Ib–IIa, <3 tumors, no major vascular invasion ...
Sportschosun on MSN
Measuring the degree of liver cancer immune cell exhaustion and predicting the effectiveness of immu...
Professor Jang Jung-won of the Department of Gastroenterology at Seoul St. Mary's Hospital of Catholic University and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback